Australia markets closed

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1600+0.0200 (+1.75%)
At close: 04:00PM EST
1.2119 +0.05 (+4.47%)
After hours: 07:51PM EST

Novan, Inc.

4020 Stirrup Creek Drive
Suite 110
Durham, NC 27703
United States
919 485 8080
https://www.novan.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees29

Key executives

NameTitlePayExercisedYear born
Ms. Paula Brown Stafford M.P.H.Pres, CEO & Chairwoman1.01MN/A1965
Mr. John M. Gay CPACFO & Corp. Sec.482.26kN/A1976
Mr. Brian M. JohnsonChief Commercial Officer443kN/A1966
Mr. John A. Donofrio Jr.Exec. VP, COO & Pres of EPI HealthN/AN/A1967
Mr. Andrew J. NovakVP of Accounting & Bus. Operations and Chief Accounting OfficerN/AN/AN/A
Dr. Carri Geer Ph.D.Sr. VP & CTON/AN/AN/A
Mr. Cole IkkalaDirector of Investor Relations, Communications & Bus. Devel.N/AN/AN/A
Mr. Stanley Hollenbach BS, J.D.Sr. VP of R&DN/AN/AN/A
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate governance

Novan, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.